echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > ZM-H1505R, an anti-hepatitis B virus nuclear casing inhibitor, was approved clinically

    ZM-H1505R, an anti-hepatitis B virus nuclear casing inhibitor, was approved clinically

    • Last Update: 2021-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 16, 2020, according to the latest publicity from the Drug Review Center (CDE) of the State Drug Administration of China, ZM-H1505R, a new class of drug declared by Shanghai-based ZM-H1505R, obtained a clinical trial to conduct safety and anti-hepatitis B virus effectiveness trials in patients with chronic hepatitis B.
    according to company-released information, the company obtained the FDA's ZM-H1505R clinical trial license on January 14 this year, and in February in the United States in healthy people launched a clinical Ia trial.
    that the Ia clinical trial has been completed, and some of the results of the clinical study were presented at this month's U.S. Liver Conference.
    photo source: CDE official website screenshots are different from other types I (sacin) and II (sulfonamide) HBV core protein variant regulator (CpAMs), ZM-H1505R is A completely new structure of pyridoxine-like nuclear crust inhibitors, by interfering with the normal formation of viral nuclear casings and hindering the packaging of pre-genome RNA (PgRNA), and effectively block the replication of hepatitis B virus, and effectively block the formation of HBV cccDNA.
    ZM-H1505R is the first clinical product to enter the HBV development pipeline for The League Pharmaceuticals.
    In the field of chronic hepatitis B treatment, Pharma's product pipeline covers multiple aspects of the life cycle of the hepatitis B virus, including antiviral replication of nuclear casing inhibitors, RNA destabilizers that inhibit the expression of surface antigens and other proteins of the hepatitis B virus, and immunomodulation agents.
    it is learned that the development strategy of the company is to suppress the replication of the virus in many directions, the expression of viral proteins, while inducing an effective antiviral immune response to suppress the virus, and ultimately achieve a functional cure of chronic hepatitis B.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.